Avacta Group Plc’s (AVCT) “Corporate” Rating Reiterated at FinnCap
FinnCap restated their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a research report released on Wednesday morning. The brokerage currently has a GBX 200 ($2.65) price objective on the biotechnology company’s stock.
Shares of Avacta Group Plc (LON:AVCT) opened at 71.50 on Wednesday. The stock’s 50 day moving average price is GBX 73.00 and its 200 day moving average price is GBX 79.91. The stock’s market capitalization is GBX 48.90 million. Avacta Group Plc has a one year low of GBX 60.00 and a one year high of GBX 98.00.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/avacta-group-plcs-avct-corporate-rating-reiterated-at-finncap/1614150.html.
In related news, insider Alastair Smith acquired 33,225 shares of the stock in a transaction on Monday, August 21st. The shares were bought at an average price of GBX 75 ($0.99) per share, with a total value of £24,918.75 ($33,053.12).
Avacta Group Plc Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.